يعرض 1 - 10 نتائج من 61 نتيجة بحث عن '"Benzaquén, Ana"', وقت الاستعلام: 0.98s تنقيح النتائج
  1. 1
  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, DiSilvestro P Program in Women's Oncology, Women & Infants Hospital, Providence, RI. Banerjee S The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom. Colombo N University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS, Milan, Italy. Scambia G Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. Kim BG Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Oaknin A Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Journal of Clinical Oncology;41(3); https://doi.org/10.1200/JCO.22.01549Test; DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2023 Jan 20;41(3):609–17.; https://hdl.handle.net/11351/9399Test; 000928326300022

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Santin AD Yale School of Medicine, New Haven, CT, USA. Vergote I University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. González-Martín A Clinica Universidad de Navarra, Madrid, Spain. Moore K University of Oklahoma Health Sciences Center, Oklahoma, OK, USA. Oaknin A Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Romero I Instituto Valenciano de Oncología, Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: International Journal of Gynecological Cancer;33(4); http://dx.doi.org/10.1136/ijgc-2022-003927Test; Santin AD, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, et al. Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. Int J Gynecol Cancer. 2023 Apr;33(4):562–70.; https://hdl.handle.net/11351/9375Test; 000904327300001

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Grau-Bejar JF, Garcia-Duran C, Garcia-Illescas D, Mirallas O Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Oaknin A Head of Gynaecological Cancer Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Therapeutic Advances in Medical Oncology;15; https://doi.org/10.1177/17588359231163836Test; Grau-Bejar JF, Garcia-Duran C, Garcia-Illescas D, Mirallas O, Oaknin A, et al. Advances in immunotherapy for cervical cancer. Ther Adv Med Oncol. 2023 Mar 28;15:1–18.; https://hdl.handle.net/11351/9422Test; 000959589400001

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Tewari KS University of California, Irvine Medical Center, Orange, CA, USA. Sill MW, Huang H Roswell Park Comprehensive Cancer Center, State University of New York at Buffalo, NY, USA. Birrer MJ University of Arkansas for Medical Sciences, Little Rock, AR, USA. Penson RT Massachusetts General Hospital, Boston, MA, USA. Moore DH Franciscan S. Francis Health, Indianapolis, IN, USA. Oaknin A Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Gynecologic Oncology;171; https://doi.org/10.1016/j.ygyno.2023.01.010Test; Tewari KS, Sill MW, Birrer MJ, Penson RT, Huang H, Moore DH, et al. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecol Oncol. 2023 Apr;171:141–50.; https://hdl.handle.net/11351/9290Test

  6. 6
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Gilbert L McGill University Health Center-Research Institute, Montreal, Canada. Oaknin A Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Matulonis UA Dana-Farber Cancer Institute, Boston, MA, United States. Mantia-Smaldone GM Fox Chase Cancer Center, Philadelphia, PA, United States. Lim PC The Center of Hope Renown Regional Medical Center, Reno, NV, United States. Castro CM Massachusetts General Hospital, Boston, MA, United States, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Gynecologic Oncology;170; https://doi.org/10.1016/j.ygyno.2023.01.020Test; Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023 Mar;170:241–7.; https://hdl.handle.net/11351/9113Test

  7. 7
  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية
  10. 10
    دورية أكاديمية